Review: Enthesitis: New Insights into Pathogenesis, Diagnostic Modalities, and Treatment

Arthritis and Rheumatology

Volumn 68, Issue 2, 2016, Pages 312-322

  Kehl, Amy S ^a   Corr, Maripat ^b   Weisman, Michael H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; APREMILAST; CYTOKINE; LEFLUNOMIDE; METHOTREXATE; MORPHOGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VERSICAN; ANTIRHEUMATIC AGENT; BONE MORPHOGENETIC PROTEIN; INTERLEUKIN 23; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; THALIDOMIDE; TUMOR NECROSIS FACTOR;

AUTOIMMUNITY; CELL ACTIVITY; ECHOGRAPHY; ENTHESITIS; FIBROCARTILAGE; GENETIC SUSCEPTIBILITY; HISTORY OF MEDICINE; MECHANICAL STRESS; MEDICAL TERMINOLOGY; MICROBIAL ACTIVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPONDYLARTHRITIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; IMMUNOLOGY; RHEUMATIC DISEASES; SPONDYLARTHROPATHIES; TENDINOPATHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNITY; BONE MORPHOGENETIC PROTEINS; CYTOKINES; FIBROCARTILAGE; HUMANS; INTERLEUKIN-23; INTERLEUKINS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; RHEUMATIC DISEASES; RITUXIMAB; SPONDYLARTHROPATHIES; TENDINOPATHY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VERSICANS;

EID: 84956727064     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39458     Document Type: Review

References (100)

1. Lampman JH., Origin of enthesopathy. J Rheumatol 1985; 12: 1030-1.
2. Ball J., Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30: 213-23.
3. Francois RJ, Braun J, Khan MA., Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol 2001; 13: 255-64.
4. Benjamin M, Moriggl B, Brenner E, Emery P, McGonagle D, Redman S., The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum 2004; 50: 3306-13.
5. McGonagle D, Stockwin L, Isaacs J, Emery P., An enthesitis based model for the pathogenesis of spondyloarthropathy: additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol 2001; 28: 2155-9.
6. Benjamin M, McGonagle D., The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 2001; 199: 503-26.
7. McGonagle D., Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23 Suppl 1: 9-13.
8. McGonagle D, Lories RJ, Tan AL, Benjamin M., The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-91.
9. Benjamin M, McGonagle D., The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009; 649: 57-70.
10. Thomopoulos S, Kim HM, Rothermich SY, Biederstadt C, Das R, Galatz LM., Decreased muscle loading delays maturation of the tendon enthesis during postnatal development [published erratum appears in J Orthop Res 2009;27:141] J Orthop Res 2007; 25: 1154-63.
11. Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M, et al., Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014; 73: 437-45.
12. Benjamin M, Rufai A, Ralphs JR., The mechanism of formation of bony spurs (enthesophytes) in the Achilles tendon. Arthritis Rheum 2000; 43: 576-83.
13. McGonagle D, Marzo-Ortega H, O'Connor P, Gibbon W, Hawkey P, Henshaw K, et al., Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002; 61: 534-7.
14. Binks D, Matzelle M, Bergin D, Hodgson RJ, Tan AL, Gravallese EM, et al., The frequency of bone marrow oedema adjacent to the cruciate ligament peri-entheseal vascular channels in inflammatory and degenerative arthritis [abstract]. Arthritis Rheum 2013; 65 Suppl: S25-6.
15. Paramarta JE, van der Leij C, Gofita I, Yeremenko N, van de Sande MG, de Hair MJ, et al., Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Ann Rheum Dis 2014; 73: 735-40.
16. 2-microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum 2012; 64: 3210-9.
17. Francois RJ, Gardner DL, Degrave EJ, Bywaters EG., Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis: systematic study of specimens from patients and control subjects. Arthritis Rheum 2000; 43: 2011-24.
18. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J., Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48: 1374-84.
19. Cook JL, Purdam CR., Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009; 43: 409-16.
20. Aspenberg P., Stimulation of tendon repair: mechanical loading, GDFs and platelets: a mini-review. Int Orthop 2007; 31: 783-9.
21. Apostolakos J, Durant TJ, Dwyer CR, Russell RP, Weinreb JH, Alaee F, et al., The enthesis: a review of the tendon-to-bone insertion. Muscles Ligaments Tendons J 2014; 4: 333-42.
22. Reveille JD., The genetic basis of spondyloarthritis. Ann Rheum Dis 2011; 70 Suppl 1: i44-50.
23. Colbert RA, Tran TM, Layh-Schmitt G., HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol 2014; 57: 44-51.
24. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA., HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60: 2633-43.
25. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al., Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun 2015; 6: 7146.
26. Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O., Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 2014. E-pub ahead of print.
27. Breban M, Costantino F, Andre C, Chiocchia G, Garchon HJ., Revisiting MHC genes in spondyloarthritis. Current Rheumatology Reports 2015; 17: 516.
28. Hacker G, Redecke V, Hacker H., Activation of the immune system by bacterial CpG-DNA. Immunology 2002; 105: 245-51.
29. Jacques P, Van Praet L, Carron P, Van den Bosch F, Elewaut D., Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am 2012; 38: 569-82.
30. Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, et al., Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012; 14: R261.
31. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al., The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-64.
32. Costello ME, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, et al., Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 2015; 67: 686-91.
33. Guerassimov A, Zhang Y, Banerjee S, Cartman A, Webber C, Esdaile J, et al., Autoimmunity to cartilage link protein in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 1998; 25: 1480-4.
34. Shi SL, Ciurli C, Cartman A, Pidoux I, Poole AR, Zhang Y., Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 2003; 48: 2903-15.
35. Zhang YP, Guerassimov A, Leroux JY, Cartman A, Webber C, Lalic R, et al., Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of T and B cell epitopes. J Clin Invest 1998; 101: 1678-86.
36. Lories RJ, Derese I, Luyten FP., Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115: 1571-9.
37. Braem K, Carter S, Lories RJ., Spontaneous arthritis and ankylosis in male DBA/1 mice: further evidence for a role of behavioral factors in "stress-induced arthritis". Biol Proced Online 2012; 14: 10.
38. Lories RJ, Derese I, Ceuppens JL, Luyten FP., Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 2003; 48: 2807-18.
39. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al., Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329-37.
40. Reveille JD., Genetics of spondyloarthritis-beyond the MHC. Nat Rev Rheumatol 2012; 8: 296-304.
41. - entheseal resident T cells. Nat Med 2012; 18: 1069-76.
42. Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Canete JD, et al., Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64: 99-109.
43. + cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13: R95.
44. Lories RJ, McInnes I., Primed for inflammation: enthesis resident cells. Nat Med 2012; 18: 1018-9.
45. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, et al., β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum 2012; 64: 2211-22.
46. Rehaume LM, Mondot S, Aguirre de Carcer D, Velasco J, Benham H, Hasnain SZ, et al., ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. Arthritis Rheumatol 2014; 66: 2780-92.
47. Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al., Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014; 66: 1755-67.
48. Yamamoto M, Nakajima K, Takaishi M, Kitaba S, Magata Y, Kataoka S, et al., Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol 2015; 135: 445-53.
49. Khmaladze I, Kelkka T, Guerard S, Wing K, Pizzolla A, Saxena A, et al., Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A 2014; 111: E3669-78.
50. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al., The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-6.
51. Naredo E, Moller I, de Miguel E, Batlle-Gualda E, Acebes C, Brito E, et al., High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology (Oxford) 2011; 50: 1838-48.
52. Yasser R, Yasser E, Hanan D, Rasker JJ., Enthesitis in seronegative spondyloarthropathies with special attention to the knee joint by MRI: a step forward toward understanding disease pathogenesis. Clin Rheumatol 2011; 30: 313-22.
53. Weiss P, Beukelman T, Schanberg LE, Kimura Y, Colbert RA, CARRAnet Investigators. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis-specific pain across juvenile idiopathic arthritis (JIA) categories: preliminary analyses from the CARRAnet registry. Arthritis Rheum 2011; 63 Suppl: S105.
54. Weiss PF., Evaluation and treatment of enthesitis-related arthritis. Curr Med Lit Rheumatol 2013; 32: 33-41.
55. D'Agostino MA, Olivieri I., Enthesitis. Best Pract Res Clin Rheumatol 2006; 20: 473-86.
56. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M., Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003; 48: 523-33.
57. D'Agostino MA, Aegerter P, Bechara K, Salliot C, Judet O, Chimenti MS, et al., How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis 2011; 70: 1433-40.
58. Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH., Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 2008; 59: 822-32.
59. Tan S, Yao J, Flynn JA, Yao L, Ward MM., Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years. Ann Rheum Dis 2015; 74: 437-43.
60. Wiell C, Norregaard J, Szkudlarek M, Hasselquist M, Moller JM, Terslev L, et al., Ultrasonography of finger joints, tendons and entheses in patients with spondyloarthropathy: a comparison with clinical examination and MRI. Ann Rheum Dis 2005; 64 Suppl III: 327.
61. Wiell C, Norregaard J, Szkudlarek M, Hasselquist M, Moller JM, Terslev L, et al., Ultrasonography of lower extremity tendons and entheses in patients with spondyloarthropathy: a comparison with clinical examination and MRI. Ann Rheum Dis 2005; 64 Suppl III: 378.
62. Amor B, Dougados M, Mijiyawa M., Criteria for the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990; 57: 85-9. In French.
63. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
64. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC., Studies with an enthesis index as a method of clinical-assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46: 197-202.
65. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al., Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32.
66. Klauser AS, Wipfler E, Dejaco C, Moriggl B, Duftner C, Schirmer M., Diagnostic values of history and clinical examination to predict ultrasound signs of chronic and acute enthesitis. Clin Exp Rheumatol 2008; 26: 548-53.
67. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J., Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37: 1039-45.
68. McGonagle D, Marzo-Ortega H, O'Connor P, Gibbon W, Pease C, Reece R, et al., The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum 2002; 46: 489-93.
69. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P., Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7.
70. Aquino MR, Tse SML, Gupta S, Rachlis AC, Stimec J., Whole-body MRI of juvenile spondyloarthritis: protocols and pictorial review of characteristic patterns. Pediatr Radiol 2015; 45: 754-62.
71. Poggenborg RP, Eshed I, Ostergaard M, Sorensen IJ, Moller JM, Madsen OR, et al., Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by 'head-to-toe' whole-body MRI and clinical examination. Ann Rheum Dis 2014; 74: 823-9.
72. Bandinelli F, Prignano F, Bonciani D, Bartoli F, Collaku L, Candelieri A, et al., Ultrasound detects occult entheseal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. Clin Exp Rheumatol 2013; 31: 219-24.
73. Ruta S, Gutierrez M, Pena C, Garcia M, Arturi A, Filippucci E, et al., Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study. J Clin Rheumatol 2011; 17: 18-22.
74. Feydy A, Lavie-Brion MC, Gossec L, Lavie F, Guerini H, Nguyen C, et al., Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis 2012; 71: 498-503.
75. De Miguel E, Munoz-Fernandez S, Castillo C, Cobo-Ibanez T, Martin-Mola E., Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Ann Rheum Dis 2011; 70: 434-9.
76. De Miguel E, Falcao S, Castillo C, Plasencia C, Garcia M, Branco JC, et al., Enthesis erosion in spondyloarthritis is not a persistent structural lesion. Ann Rheum Dis 2011; 70: 2008-10.
77. Naredo E, Batlle-Gualda E, Garcia-Vivar ML, Garcia-Aparicio AM, Fernandez-Sueiro JL, Fernandez-Prada M, et al., Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities. J Rheumatol 2010; 37: 2110-7.
78. D'Agostino MA, Breban M, Said-Nahal R, Dougados M., Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound [letter]. Arthritis Rheum 2002; 46: 840-1.
79. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al., Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71: 1616-22.
80. Kroon F, Landewe R, Dougados M, van der Heijde D., Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71: 1623-9.
81. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al., 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
82. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al., Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64: 1568-75.
83. Baraliakos X, Davis J, Tsuji W, Braun J., Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216-23.
84. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al., Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.
85. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, and M02-570 Study Group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy [published erratum appears in J Rheumatol 2007;34:1439]. J Rheumatol 2007; 34: 1040-50.
86. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al., Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study [published erratum appears in Arthritis Rheum 2010;62:2555] Arthritis Rheum 2009; 60: 976-86.
87. Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al., Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-9.
88. Olivieri I, Giasi V, Scarano E, Gigliotti P, D'Angelo S, Padula A., A brief course of anti-TNF-α therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis [letter]. Clin Exp Rheumatol 2009; 27: 1057.
89. Hreggvidsdottir HS, Noordenbos T, Baeten DL., Inflammatory pathways in spondyloarthritis. Mol Immunol 2014; 57: 28-37.
90. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al., Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
91. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al., Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing [abstract]. Arthritis Rheumatol 2014; 66: 3529.
92. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al., Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 2015; 42: 479-88.
93. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, et al., Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144-55.
94. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al., A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51: 1368-77.
95. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al, for the Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-50.
96. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al., Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
97. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al., Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108-10.
98. Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, et al., Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther 2012; 14: R53.
99. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, et al., One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013; 72: 305-6.
100. Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, et al, on behalf of the French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012; 39: 2327-31.